Ribosome biogenesis in disease: new players and therapeutic targets
Abstract The ribosome is a multi-unit complex that translates mRNA into protein. Ribosome biogenesis is the process that generates ribosomes and plays an essential role in cell proliferation, differentiation, apoptosis, development, and transformation. The mTORC1, Myc, and noncoding RNA signaling pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-01-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-022-01285-4 |
| _version_ | 1828063523549216768 |
|---|---|
| author | Lijuan Jiao Yuzhe Liu Xi-Yong Yu Xiangbin Pan Yu Zhang Junchu Tu Yao-Hua Song Yangxin Li |
| author_facet | Lijuan Jiao Yuzhe Liu Xi-Yong Yu Xiangbin Pan Yu Zhang Junchu Tu Yao-Hua Song Yangxin Li |
| author_sort | Lijuan Jiao |
| collection | DOAJ |
| description | Abstract The ribosome is a multi-unit complex that translates mRNA into protein. Ribosome biogenesis is the process that generates ribosomes and plays an essential role in cell proliferation, differentiation, apoptosis, development, and transformation. The mTORC1, Myc, and noncoding RNA signaling pathways are the primary mediators that work jointly with RNA polymerases and ribosome proteins to control ribosome biogenesis and protein synthesis. Activation of mTORC1 is required for normal fetal growth and development and tissue regeneration after birth. Myc is implicated in cancer development by enhancing RNA Pol II activity, leading to uncontrolled cancer cell growth. The deregulation of noncoding RNAs such as microRNAs, long noncoding RNAs, and circular RNAs is involved in developing blood, neurodegenerative diseases, and atherosclerosis. We review the similarities and differences between eukaryotic and bacterial ribosomes and the molecular mechanism of ribosome-targeting antibiotics and bacterial resistance. We also review the most recent findings of ribosome dysfunction in COVID-19 and other conditions and discuss the consequences of ribosome frameshifting, ribosome-stalling, and ribosome-collision. We summarize the role of ribosome biogenesis in the development of various diseases. Furthermore, we review the current clinical trials, prospective vaccines for COVID-19, and therapies targeting ribosome biogenesis in cancer, cardiovascular disease, aging, and neurodegenerative disease. |
| first_indexed | 2024-04-10T22:44:49Z |
| format | Article |
| id | doaj.art-607d7d6e33204f70bbd9ca83eedffe42 |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-04-10T22:44:49Z |
| publishDate | 2023-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-607d7d6e33204f70bbd9ca83eedffe422023-01-15T12:22:32ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352023-01-018112210.1038/s41392-022-01285-4Ribosome biogenesis in disease: new players and therapeutic targetsLijuan Jiao0Yuzhe Liu1Xi-Yong Yu2Xiangbin Pan3Yu Zhang4Junchu Tu5Yao-Hua Song6Yangxin Li7Institute for Cardiovascular Science and Department of Cardiovascular Surgery, First Affiliated Hospital and Medical College of Soochow University, Collaborative Innovation Center of Hematology, Soochow UniversityDepartment of Orthopedics, the Second Hospital of Jilin UniversityKey Laboratory of Molecular Target & Clinical Pharmacology and the NMPA State Key Laboratory of Respiratory Disease, Guangzhou Medical UniversityDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeInstitute for Cardiovascular Science and Department of Cardiovascular Surgery, First Affiliated Hospital and Medical College of Soochow University, Collaborative Innovation Center of Hematology, Soochow UniversityInstitute for Cardiovascular Science and Department of Cardiovascular Surgery, First Affiliated Hospital and Medical College of Soochow University, Collaborative Innovation Center of Hematology, Soochow UniversityCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow UniversityInstitute for Cardiovascular Science and Department of Cardiovascular Surgery, First Affiliated Hospital and Medical College of Soochow University, Collaborative Innovation Center of Hematology, Soochow UniversityAbstract The ribosome is a multi-unit complex that translates mRNA into protein. Ribosome biogenesis is the process that generates ribosomes and plays an essential role in cell proliferation, differentiation, apoptosis, development, and transformation. The mTORC1, Myc, and noncoding RNA signaling pathways are the primary mediators that work jointly with RNA polymerases and ribosome proteins to control ribosome biogenesis and protein synthesis. Activation of mTORC1 is required for normal fetal growth and development and tissue regeneration after birth. Myc is implicated in cancer development by enhancing RNA Pol II activity, leading to uncontrolled cancer cell growth. The deregulation of noncoding RNAs such as microRNAs, long noncoding RNAs, and circular RNAs is involved in developing blood, neurodegenerative diseases, and atherosclerosis. We review the similarities and differences between eukaryotic and bacterial ribosomes and the molecular mechanism of ribosome-targeting antibiotics and bacterial resistance. We also review the most recent findings of ribosome dysfunction in COVID-19 and other conditions and discuss the consequences of ribosome frameshifting, ribosome-stalling, and ribosome-collision. We summarize the role of ribosome biogenesis in the development of various diseases. Furthermore, we review the current clinical trials, prospective vaccines for COVID-19, and therapies targeting ribosome biogenesis in cancer, cardiovascular disease, aging, and neurodegenerative disease.https://doi.org/10.1038/s41392-022-01285-4 |
| spellingShingle | Lijuan Jiao Yuzhe Liu Xi-Yong Yu Xiangbin Pan Yu Zhang Junchu Tu Yao-Hua Song Yangxin Li Ribosome biogenesis in disease: new players and therapeutic targets Signal Transduction and Targeted Therapy |
| title | Ribosome biogenesis in disease: new players and therapeutic targets |
| title_full | Ribosome biogenesis in disease: new players and therapeutic targets |
| title_fullStr | Ribosome biogenesis in disease: new players and therapeutic targets |
| title_full_unstemmed | Ribosome biogenesis in disease: new players and therapeutic targets |
| title_short | Ribosome biogenesis in disease: new players and therapeutic targets |
| title_sort | ribosome biogenesis in disease new players and therapeutic targets |
| url | https://doi.org/10.1038/s41392-022-01285-4 |
| work_keys_str_mv | AT lijuanjiao ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT yuzheliu ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT xiyongyu ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT xiangbinpan ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT yuzhang ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT junchutu ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT yaohuasong ribosomebiogenesisindiseasenewplayersandtherapeutictargets AT yangxinli ribosomebiogenesisindiseasenewplayersandtherapeutictargets |